Fully Enrolled Second Cohort in Phase 2 Basket Study of WAL0921 In Chronic Kidney Disease Plans to Initiate Rare Kidney Diseases Cohort in Early 2025 Company to Attend 43rd Annual J.P. Morgan ...

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma ...

Additional clinical results from Phase 1/2 study of MRT-2359 in MYC-driven solid tumors, including biomarker and activity data, anticipated in Q1 2025 MRT-8102, a NEK7-directed MGD targeting diseases ...

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.